In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Pfizer is taking a more hands-on approach to AI in drug research, teaming up with startup Boltz to help its scientists make ...

Pfizer (PFE) has entered into an agreement with Boltz to use the latter's biomolecular AI foundation models to tap into the ...

In this week’s edition of The Prototype, we look at building a virtual fusion power plant, a major quantum breakthrough, AI ...

At the inaugural Columbia SPS Faculty Summit on AI Teaching and Learning, faculty and industry experts explored AI’s emerging ...

AI and digital health devices should not be viewed as replacements for health care professionals, but as tools that can be ...

PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill ...

MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.

The alliance with Paris, France-based Iktos could be worth more than €1 billion in upfront, research funding, and milestone ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

TEL AVIV, Israel, Jan. 9, 2026 /PRNewswire/ -- CytoReason, a leader in AI-powered computational disease modeling, today announced the expansion of its collaboration with Sanofi for the third time.